All News

COVID,nasal,PCR,test,swab

MMWR - NFL Study on When to Be Released if COVID(+)

d Jack Cush, MD

MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021, at the height of the Omicron variant surge, showing that among those with asymptomatic infection, only half were PCR test negative and could return to

Read Article
RheumNow Podcast square

Diagnostic Delay in Axial Spondyloarthritis (2.25.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live.

Read Article
PSA2L.jpg

COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis

d Jack Cush, MD

Guselkumab, an IL-2319-subunit antibody, was studied in active psoriatic arthritis (PsA) patients who had a previously inadequate response (IR) to tumour necrosis factor inhibitors (TNFi) and after 1 year was shown to significantly improved joint and skin manifestations and physical function.

Read Article
SLE,malar,black

ACR Addresses Racial Disparities in Lupus Trials

d ACR

The American College of Rheumatology (ACR) is launching two new initiatives to reduce racial disparities in lupus clinical trials: Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY) and new Continuing Medical Educatio

Read Article
COVID,vaccinate,injection,green

Low COVID-19 Vaccine Risks in Rheumatic Patients

d Jack Cush, MD

Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine registry shows that patients with with inflammatory or noninflammatory rheumatic and musculoskeletal disease have similar adverse event rates as the general public.

Read Article
smiley-2979107_640_0.jpg

Medscape: Physician Burnout Report 2022

d Jack Cush, MD

The annual Medscape Physician Burnout & Depression survey has been published for 2022 and Rheumatology burnout stats have improved, now ranking 10th (middle of the pack). 

Read Article
ICYMI: 144 SLE pts from the SLICC cohort were studied showing that a majority (61.2%) scores consistent with depression over 4 yrs; also an inconsistent association between disease activity and depression in multivariate analysis https://t.co/YqxPFtYohf

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Case showing flare of Dermatomyositis in a Patient With Psoriasis treated with Secukinumab. https://t.co/GvyXzcSNUa https://t.co/T83m5YojcH

Links:

Dr. John Cush RheumNow ( View Tweet)
In case you missed it… RA: Still a Clinical Diagnosis https://t.co/8RrhxAgbkP https://t.co/R9EpxSE9Gr

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Positive Results from the DOA (Duloxetine in OsteoArthritis) Study https://t.co/JU0OeQgmta https://t.co/IRv3C747Zt

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast available for download! Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week, rheumatologic problems incited by respiratory infections, air pollution and how you live, now where you live. https://t.co/jQAq6iBvca https://t.co/FgIG1ogPGo

Links:

Dr. John Cush RheumNow ( View Tweet)
We are excited to share that Kaleb Michaud, PhD, will be presenting on Adherence to Rheumatoid Therapies during our RA-Future Improvement Pod at RheumNow Live on 3/19. Have you registered yet? https://t.co/HOOMh84MF0 https://t.co/5lPijPoN9b

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR - NFL Study on When to Be Released if COVID(+) MMWR has reported the results of the National Football Leagues (NFL) change in SARS-CoV-2 testing program that went into effect in December 2021. https://t.co/EoIjc0XL0R https://t.co/ysRPao1oC2

Links:

Dr. John Cush RheumNow ( View Tweet)
COSMOS Study - Guselkumab Efficacy at 1 Year in Psoriatic Arthritis https://t.co/kl6RzE6hK2 https://t.co/vLY2xQAqwn

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA granted Breakthrough Therapy Designation Boehringer Ingelheims BI 1015550 - a oral, phosphodiesterase 4B inhibitor (antifibrotic & anti-inflammatory), now in phase II trials for idiopathic pulmonary fibrosis https://t.co/SMXEweSVAR

Links:

Dr. John Cush RheumNow ( View Tweet)

SLE mortality rates (ASMR) nearly doubled since 1998 & remain high (vs non-SLE mortality) w/ significant sex & regional disparities. Data from 11449 SLE deaths, ASMR signif increased 1998 to 2009, down 2009 to 2013 and increased thereafter https://t.co/kSc3Cn2Bl5

Links:

Dr. John Cush RheumNow ( View Tweet)

Diagnostic delay in axial spondyloarthritis? Systematic review shows Dx delay ranged 0.67 to 8 years (>75% =,2-6 yrs). Only 1/3 had median delay ~ 2 yrs. Gender and +FamHx did not influence Dx Delay. https://t.co/R5WwCvZPzc

Links:

Dr. John Cush RheumNow ( View Tweet)

Where you live doesn't alter your risk for RA. Systematic review of 54 articles, 11 studies shows that rural/remote populations had no greater #RA risk. But Rural/remote pts have >barriers to care which increases the risk for inequities in outcomes. https://t.co/8fhFSQ54rt https://t.co/qJhNFcb0b2

Links:

Dr. John Cush RheumNow ( View Tweet)
Case showing flare of Dermatomyositis in a Patient With Psoriasis treated with Secukinumab. https://t.co/uvXyqONaHl

Links:

Dr. John Cush RheumNow ( View Tweet)

Single center study of 957 plaque psoriasis pts and the effect of air pollutants. Overall 39% experience a PSO flare and that concentrations of all pollutants were significantly higher in the 60 days before psoriasis flare https://t.co/8Hw3LsLy8f

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×